Brief: I-Mab, Bristol Myers Squibb Collaborate To Evaluate Givastomig In A Combination Study For Newly Diagnosed Gastric, Esophageal Cancers
05/06/2024 12:53
June 5 (Reuters) - I-Mab IMAB.O :
* I-MAB ANNOUNCES COLLABORATION WITH BRISTOL MYERS SQUIBB TO
EVALUATE GIVASTOMIG IN A COMBINATION STUDY FOR NEWLY DIAGNOSED
GASTRIC AND ESOPHAGEAL CANCERS
* I-MAB: COLLABORATION WITH BRISTOL MYERS TO EVALUATE
CLAUDIN 18.2
X 4-1BB BISPECIFIC ANTIBODY GIVASTOMIG IN COMBINATION WITH
NIVOLUMAB AND CHEMOTHERAPY
Source text for Eikon: ID:nPn9Z7Kbja
Further company coverage: IMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview